Lenalidomide Piramal

Lenalidomide, the active ingredient in Lenalidomide Piramal, is an immunomodulatory imide drug (IMiD) presented as an oral tablet for oral use. It is used to treat certain blood cancers, specifically multiple myeloma and myelodysplastic syndromes, in adult patients.

GNH USA supplies Lenalidomide Piramal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Lenalidomide Piramal belongs to the immunomodulatory drug class and is employed in hematologic malignancies. - Multiple myeloma: improves progression‑free survival and overall response when used alone or with dexamethasone. - Myelodysplastic syndromes with del(5q): reduces transfusion dependence and induces cytogenetic remission. - Relapsed or refractory multiple myeloma: provides clinical benefit as part of combination regimens after prior therapies have failed.

Lenalidomide may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Neutropenia: decreased neutrophil count, increasing infection risk. - Thrombocytopenia: reduced platelet levels, leading to bleeding tendencies. - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools that may be mild to moderate. - Constipation: difficulty passing stools. - Rash: skin irritation or erythema.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs. - Severe neutropenia or thrombocytopenia: requiring medical intervention. - Secondary primary malignancies: emergence of new cancers. - Hepatotoxicity: elevated liver enzymes or liver injury. - Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor laboratory parameters regularly. - Pregnancy contraindication: drug is teratogenic; avoid use in pregnant women and ensure effective contraception. - Thromboembolic risk: assess need for prophylactic anticoagulation in high‑risk patients. - Hematologic monitoring: perform complete blood counts weekly until stable, then periodically. - Renal impairment: adjust dose in patients with reduced creatinine clearance. - Drug interactions: review concomitant medications for CYP3A4 modulators and anticoagulants. - Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and light.

Lenalidomide can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Thalidomide: combined teratogenic risk and additive hematologic toxicity. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase lenalidomide exposure. - Anticoagulants (e.g., warfarin): heightened risk of bleeding.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce drug efficacy. - NSAIDs: potential for increased renal toxicity. - Live vaccines: diminished immune response; avoid during treatment.